• Tetraphase enters into agreement with Biopharma firm in China biospectrumasia
    February 26, 2018
    As per the agreement, Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million as well as annual sales milestones of up to $20.0 million.
PharmaSources Customer Service